Literature DB >> 16686368

A 96-well efflux assay to identify ABCG2 substrates using a stably transfected MDCK II cell line.

Yongling Xiao1, Ralph Davidson, Arthur Smith, Dennis Pereira, Sabrina Zhao, John Soglia, David Gebhard, Sonia de Morais, David B Duignan.   

Abstract

Human ABCG2 (breast cancer resistance protein, BCRP) is an important efflux transporter which exhibits broad substrate specificity and which is found in many tissues. The purpose of the present study was to develop a 96-Transwell assay using an MDCK II cell line stably transfected with ABCG2 (MDCK II/ABCG2) to identify ABCG2 substrates. In this assay, which also incorporates a high throughput mass spectrometry method for quantification, efflux activity of the MDCK II/ABCG2 cells was evaluated by monitoring the basolateral-to-apical/ apical-to-basolateral (B to A/A to B) efflux ratio of several substrates. Mean MDCK II/ABGC2 efflux ratios for 2 microM prazosin, SN-38, and Cl 033 were 2.8, 7.6, and 2.4, respectively, and the mean efflux ratio for 10 microM mitoxantrone was 5.0. Interday variability of the assay was low (CV = 10-29% for control compounds at 2 microM). Our data indicate that a compound tested at 2 microM can be considered a substrate of ABCG2 if its ratio of ratios (MDCK II/ABCG2 efflux ratio)/ (MDCK II efflux ratio) is > 1.2. This assay provides an efficient, high throughput means to identify ABCG2 substrates in drug discovery.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16686368     DOI: 10.1021/mp050088t

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  10 in total

1.  Effects of single and multiple flavonoids on BCRP-mediated accumulation, cytotoxicity and transport of mitoxantrone in vitro.

Authors:  Guohua An; Marilyn E Morris
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

2.  Prediction of Drug Clearance from Enzyme and Transporter Kinetics.

Authors:  Priyanka R Kulkarni; Amir S Youssef; Aneesh A Argikar
Journal:  Methods Mol Biol       Date:  2021

3.  Fusidic Acid Inhibits Hepatic Transporters and Metabolic Enzymes: Potential Cause of Clinical Drug-Drug Interaction Observed with Statin Coadministration.

Authors:  Anshul Gupta; Jennifer J Harris; Jianrong Lin; James P Bulgarelli; Bruce K Birmingham; Scott W Grimm
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

Review 4.  Advancement of structure-activity relationship of multidrug resistance-associated protein 2 interactions.

Authors:  Li Xing; Yiding Hu; Yurong Lai
Journal:  AAPS J       Date:  2009-06-03       Impact factor: 4.009

5.  Unconjugated bilirubin elevation impairs the function and expression of breast cancer resistance protein (BCRP) at the blood-brain barrier in bile duct-ligated rats.

Authors:  Ping Xu; Zhao-Li Ling; Ji Zhang; Ying Li; Nan Shu; Ze-Yu Zhong; Yang Chen; Xin-Yu Di; Zhong-Jian Wang; Li Liu; Xiao-Dong Liu
Journal:  Acta Pharmacol Sin       Date:  2016-05-16       Impact factor: 6.150

6.  Antipsychotic drugs inhibit the function of breast cancer resistance protein.

Authors:  Jun-Sheng Wang; Hao-Jie Zhu; John S Markowitz; Jennifer L Donovan; Hong-Jie Yuan; C Lindsay Devane
Journal:  Basic Clin Pharmacol Toxicol       Date:  2008-10       Impact factor: 4.080

7.  Influence of overexpression of efflux proteins on the function and gene expression of endogenous peptide transporters in MDR-transfected MDCKII cell lines.

Authors:  Zhiying Wang; Dhananjay Pal; Ashaben Patel; Deep Kwatra; Ashim K Mitra
Journal:  Int J Pharm       Date:  2012-12-20       Impact factor: 5.875

8.  Effects of α-adrenoceptor antagonists on ABCG2/BCRP-mediated resistance and transport.

Authors:  Kohji Takara; Kazuhiro Yamamoto; Mika Matsubara; Tetsuya Minegaki; Minoru Takahashi; Teruyoshi Yokoyama; Katsuhiko Okumura
Journal:  PLoS One       Date:  2012-02-15       Impact factor: 3.240

Review 9.  Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.

Authors:  Takeo Nakanishi; Douglas D Ross
Journal:  Chin J Cancer       Date:  2011-11-18

10.  Screening compounds with a novel high-throughput ABCB1-mediated efflux assay identifies drugs with known therapeutic targets at risk for multidrug resistance interference.

Authors:  Megan R Ansbro; Suneet Shukla; Suresh V Ambudkar; Stuart H Yuspa; Luowei Li
Journal:  PLoS One       Date:  2013-04-10       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.